RxDoctor Payments Data

Jennifer Simonds

Psychiatric/Mental Health, Adult · Augusta, GANPI 1437477262

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.6% of the total across 75 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by AbbVie at 29.9% of the total. Reporting peaked in 2022 at $659 and has fallen 86.7% since, to $88 in 2025.

$1,214in general payments, 2019–2025

Across 75 payments — averaging $16.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$363
  • Takeda Pharmaceuticals U.S.A., Inc.$297
  • Otsuka America Pharmaceutical, Inc.$159
  • Johnson & Johnson$145
  • Sunovion Pharmaceuticals Inc.$98
  • Lundbeck LLC$66
  • plus $88 from 4 others

What the payments were for

  • Food & beverage$1,209100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,214 in reported general payments places this provider in the 85th percentile of 22 psychiatric/mental health, adult providers in Georgia.

See all psychiatric/mental health, adult providers in Georgia

Medicare billing

Part B allowed, 2024
$18,444
Medicare patients
43
Services billed
203

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrintellixVortioxetine Hydrobromide48$29,353
RexultiBrexpiprazole11$16,011
Lurasidone Hcl16$13,079
AuvelityDextromethorphan Hbr/Bupropion13$12,765
DayvigoLemborexant12$3,982
Duloxetine Hcl43$3,532
Ramelteon18$3,045
Ziprasidone Hcl21$1,553
Olanzapine61$1,318
Quetiapine Fumarate80$820
Buspirone Hcl55$768
Clonazepam119$716
Mirtazapine42$701
Bupropion XlBupropion Hcl39$597
Risperidone16$482

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$297$29,35348 claims
Otsuka America Pharmaceutical, Inc.Rexulti$159$16,01111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 22 psychiatric/mental health, adult providers in Georgia.

Other psychiatric/mental health, adult in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →